Abstract: The present disclosure relates to certain (2S)—N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.

Abstract: System and methods for synchronizing and encrypting profile information are provided. A method establishes a first browser instance on a first virtual machine being in communication with a first browser profile sync and encrypt agent. The method also establishes a second browser instance on a second virtual machine. The method may use the first browser profile sync and encrypt agent acting through a profile helper service to encrypt profile changes involving the first browser instance on an encrypted master profile and use the second browser profile sync and encrypt agent acting through the profile helper service to encrypt profile changes involving the second browser instance on the encrypted master profile. The method maintains a browser profile persistence for the first browser instance and for the second browser instance, using the encrypted master profile, on a single on-disk profile.

Abstract: The present disclosure relates to certain (2S)—N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.

Abstract: The present disclosure relates to certain (2S)—N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.

Abstract: A mobile device mounting system includes a device case and a mount. The device case includes: an insert including a rectangular bore and defining a set of undercut sections about the rectangular bore; and a first set of magnetic elements arranged in a first pattern about the rectangular bore. The mount includes: a body; a polygonal boss extending from the body and configured to insert into the rectangular bore; a set of locking jaws arranged on the polygonal boss configured to transiently mate with the set of undercut sections to constrain the polygonal boss within the rectangular bore; and a second set of magnetic elements arranged in a second pattern about the polygonal boss and configured to transiently couple to the first set of magnetic elements to transiently retain the mount against the device case and to drive the set of locking jaws toward the set of undercut sections.

Abstract: There is provided a connecting interface for fluidically interconnecting microfluidic channels. The connecting interface comprises one or more substrates which collectively define a first microfluidic channel which includes a connecting region for fluidically connecting the first microfluidic channel to a second microfluidic channel. The connecting interface further comprises at least one slit in an outer surface of one of the one or more substrates, wherein the at least one slit provides a fluid passage from the outer surface to the connecting region of the first microfluidic channel, and the at least one slit has at least one dimension extending beyond the connecting region along a direction parallel to the outer surface.

Abstract: A mobile device mounting system includes a device case and a mount. The device case includes: an insert including a rectangular bore and defining a set of undercut sections about the rectangular bore; and a first set of magnetic elements arranged in a first pattern about the rectangular bore. The mount includes: a body; a polygonal boss extending from the body and configured to insert into the rectangular bore; a set of locking jaws arranged on the polygonal boss configured to transiently mate with the set of undercut sections to constrain the polygonal boss within the rectangular bore; and a second set of magnetic elements arranged in a second pattern about the polygonal boss and configured to transiently couple to the first set of magnetic elements to transiently retain the mount against the device case and to drive the set of locking jaws toward the set of undercut sections.

Abstract: The present disclosure relates to certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD) , to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.

Abstract: A method for the prediction, prognosis and/or diagnosis of bladder cancer or bladder cancer recurrence in a subject, the method includes: providing a test sample from the subject; measuring DNA methylation levels of at least a portion of two or more polynucleotides selected from the group consisting of HOXA9, SOX1, NPY, IRAK3, L1-MET, and ZO2 in the test sample; calculating a risk score based on the measured DNA methylation levels, comparing the calculated risk score to a cut-off value derived from a reference DNA methylation profile based on DNA methylation levels of the one or more biomarkers derived from a control group, members of which had bladder cancer; and based on the comparison calculated risk score to the cut-off value, determining at least one of: (1) whether bladder cancer has recurred; (2) whether there is likelihood that the bladder cancer will recur; and (3) whether the patient has bladder cancer.

Abstract: The present disclosure relates to certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.

Abstract: The present disclosure relates to certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.

Abstract: The present invention relates to boron containing compounds of Formula (IA): that inhibit phosphodiesterase 4 (PDE4). The invention also encompasses pharmaceutical compositions containing these compounds and methods for treating diseases, conditions, or disorders ameliorated by inhibition of PDE4.

Abstract: A mobile device mounting system includes a device case and a mount. The device case includes: an insert including a rectangular bore and defining a set of undercut sections about the rectangular bore; and a first set of magnetic elements arranged in a first pattern about the rectangular bore. The mount includes: a body; a polygonal boss extending from the body and configured to insert into the rectangular bore; a set of locking jaws arranged on the polygonal boss configured to transiently mate with the set of undercut sections to constrain the polygonal boss within the rectangular bore; and a second set of magnetic elements arranged in a second pattern about the polygonal boss and configured to transiently couple to the first set of magnetic elements to transiently retain the mount against the device case and to drive the set of locking jaws toward the set of undercut sections.

Abstract: Disclosed herein are systems and methods for attachable-and-detachable database sessions. In an embodiment, a database platform receives an attachment request from a client during a connection-specific database session that is set as a current database session for the client at the database platform, requesting that the client attach to an attachable-and-detachable database session that is maintained in data storage by the database platform. The database platform sets, in response to receiving the attachment request, the attachable-and-detachable database session as the current database session for the client at the database platform. The database platform determines that the client has detached from the attachable-and-detachable database session, and continues to maintain the attachable-and-detachable database session in the data storage.

Abstract: The present invention relates to certain 4-(substituted aniline)-2-(substituted piperidin-1-yl)pyrimidine-5-carboxamide compounds which may be useful in the treatment or prevention of a disease or medical condition mediated through signaling of CaMK1 isoforms. For example, such compounds and salts thereof may be useful in the treatment or prevention of a number of different cancers, metabolic diseases including type-2 diabetes, and/or immune-mediated disorders.

Abstract: According to various aspects of the present disclosure, an apparatus is provided. In an aspect, the apparatus includes an optical transceiver having a first port, a second port and an optical switch coupled to the first port and the second port. The optical switch is switchable between a unidirectional port operation mode and a bidirectional port operation mode. When the optical switch is in the unidirectional port operation mode, the first port is configured to send a first optical signal, and the second port configured to receive a second optical signal. When the optical switch is in the bidirectional port operation mode, the first port configured to send the first optical signal and receive the second optical signal, and the second port configured to receive a third optical signal and not send the first signal.

Abstract: An HVAC controller provides control values to or more output ports of the HVAC controller. Operation of the HVAC controller is monitored for one or more irregularities. When one or more irregularities in the operation are identified, a hold mode is entered. The hold mode includes holding the one or more current control values on the one or more output ports of the HVAC controller until the one or more irregularities in the operation of the HVAC controller are corrected or a predetermined hold time expires, whichever occurs first. When the one or more irregularities in the operation of the HVAC controller are not corrected before the predetermined hold time expires, a back off mode is entered. The back off mode includes setting each of one or more control values on one or more output ports of the HVAC controller to a corresponding configurable back off value.

Abstract: A solenoid comprises first and second coils connected to an electrical power supply circuit. In a first mode of operation the power supply circuit is arranged to provide a current flowing in opposite directions through the respective first and second coils, e.g. to produce a self-heating effect. In a second mode of operation the power supply circuit is arranged to provide a current flowing in the same direction through the respective first and second coils, e.g. to generate a magnetic force. In some embodiments, the power supply circuit includes a bridge rectifier or full wave rectifier connected to a bi-directional current driver.

Abstract: A microfluidic device comprising a plurality of microreactors is provided. Each microreactor includes at least a first inlet and a second inlet for supplying a first fluid and a second fluid, respectively, to said microreactor and at least one waste channel for draining fluid from said microreactor. The device further comprises a shared first microfluidic supply system for supplying a first fluid to the first inlets of the plurality of microreactors, a shared second microfluidic supply system for supplying a second fluid to the second inlets of the plurality of microreactors. At least one of said inlets to each microreactor comprises at least one valve-less fluidic resistance element having a fluidic resistance that is substantially larger than the fluidic resistance of the corresponding shared microfluidic supply system. A chemical reaction sequencer apparatus including the microfluidic device and a method for supplying reagents to a plurality of microreactors are also provided.